Answers are grounded in this paper and cite their sources.
The gut microbiota forms a highly dynamic and multilayered ecological system that plays a pivotal role in maintaining mucosal immune homeostasis. When the “microbiota-immune regulatory” axis is perturbed in genetically susceptible individuals, antigen recognition and effector responses at the mucosal surface may be reshaped, thereby driving the onset and persistent progression of IBD. This review highlights the distinct patterns of microbe-immune interactions under physiological and pathological conditions, with particular focus on the key immunoregulatory events at different disease stages. In the early phase of IBD, adhesive and invasive bacterial strains and microbial dysbiosis can disrupt epithelial barriers, trigger aberrant innate immune activation, and induce chronic local inflammation. As the disease advances, T-cell polarization, tissue remodeling, and extraintestinal manifestations collectively sustain the inflammatory network and promote systemic damage. We further summarize emerging microbiota-based immunotherapeutic strategies-such as fecal microbiota transplantation, probiotics/prebiotics, targeted manipulation of specific bacterial taxa, bacteriophage therapy, and engineered probiotics-and their potential value and remaining clinical challenges in IBD management. Future work should integrate gut microbiota-immune crosstalk to identify clinically actionable targets and validate their biological and therapeutic significance through well-designed prospective studies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: